Global BioAccess Fund
Global BioAccess Fund is a New York-based venture capital firm that invests in transformative technologies addressing unmet medical needs in oncology, rare diseases, CNS disorders, and cardiology. The firm focuses on backing early-stage companies that require capital to pursue IND submissions and clinical trials, helping translate scientific discoveries into therapies. Founded in 2021, Global BioAccess Fund supports ventures at critical development milestones and seeks to advance innovative approaches across its therapeutic areas.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
3 past transactions
Nuvig Therapeutics
Series B in 2024
Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.
ShiraTronics
Series B in 2024
ShiraTronics develops neuromodulation therapies to treat chronic migraine by delivering continuous stimulation to targeted nerves to relieve, interrupt, and prevent migraine episodes. Founded in 2018 and based in Ireland, the company maintains an additional location in Minneapolis, Minnesota, and pursues innovative neuromodulation technology to address unmet neurological needs and improve patient outcomes.
Acesion Pharma
Series B in 2023
Founded in 2011, Acesion Pharma is a Danish biotech company dedicated to developing safe and tolerable treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. The company focuses on inhibiting specific ion channels in heart cells to regulate the heart's rhythm and prevent AF recurrence.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.